Trials / Unknown
UnknownNCT04383977
Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer
A Phase 2 Randomized, Open-label, Multicenter Trial of Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant or Refractory Ovarian Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is conducted to evaluate the efficacy, safety and tolerability of apatinib (375 mg qd) or apatinib (375 mg qd) and etoposide capsule (50 mg/d, d1-14, q3w) in subjects with platinum resistant or refractory ovarian cancer compared with apatinib (375 mg qd).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib and Etoposide capsule | Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity |
| DRUG | Apatinib | Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity |
Timeline
- Start date
- 2020-05-01
- Primary completion
- 2020-12-01
- Completion
- 2021-06-01
- First posted
- 2020-05-12
- Last updated
- 2020-05-12
Source: ClinicalTrials.gov record NCT04383977. Inclusion in this directory is not an endorsement.